Pyxis Oncology, Inc. — Director's Dealing 2021

Oct 8, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Pyxis Oncology, Inc. (PYXS)
CIK: 0001782223
Period of Report: 2021-10-07

Reporting Person: Yanchik Connealy Pamela (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to buy)	$8.71	2031-07-30	Common Stock (322265)		Direct
Stock Option (Right to buy)	$8.71	2031-09-14	Common Stock (10304)		Direct

Footnotes

F1: These stock options vest 25% on the first anniversary of the July 31, 2021 grant date, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

F2: These stock options vest 25% on the first anniversary of the closing of the Issuer's initial public offering, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.